This protective enzyme could help stop fatty liver disease from getting worse

Researchers have identified the UBE2N enzyme as a potential protective factor against the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Restoring this enzyme in preclinical models successfully reduced liver inflammation and scarring.
Why it matters
This discovery offers a promising new therapeutic target for a common liver condition that currently lacks a cure.
Researchers co-led by Cedars-Sinai Health Sciences University have identified an enzyme that may help protect the liver from the damage that can occur as the most common form of liver disease becomes more severe. The findings, from a preclinical study published in Nature Metabolism , could eventually support new strategies for preventing serious liver injury and progression toward liver failure.
An estimated 100 million people in the U.S. have metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease, according to the American Liver Foundation. Roughly 20% to 25% of those affected go on to develop metabolic dysfunction-associated steatohepatitis (MASH), a more serious form of the condition in which excess liver fat is accompanied by inflammation, cell injury and scarring.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in